Details of the Drug

General Information of Drug (ID: DMSA8RU)

Drug Name
Abatacept
Synonyms Orencia (TN)
Indication
Disease Entry ICD 11 Status REF
Alopecia areata ED70.2 Approved [1]
Crohn disease DD70 Approved [2]
Multiple sclerosis 8A40 Approved [3]
Rheumatoid arthritis FA20 Approved [4]
Systemic lupus erythematosus 4A40.0 Approved [5]
Therapeutic Class
Antirheumatic Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AA24: Abatacept
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Sequence
MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTF
LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPC
PDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
ADMET Property
Clearance
The sytemic clearance of drug is 0.28 mL/h/kg []
Elimination
The drug is excreted via kidney and liver []
Half-life
The concentration or amount of drug in body reduced by one-half in 16.7 (12 - 23) days [6]
Vd
The volume of distribution (Vd) of drug is 0.07 L/kg []
Cross-matching ID
UNII
7D0YB67S97
DrugBank ID
DB01281
TTD ID
D0EW4L
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation B7-1 antigen (CD80) TTFZDNP CD80_HUMAN Binder [7]
T-lymphocyte activation antigen CD86 (FUN1) TTHGXBU CD86_HUMAN Binder [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Abatacept
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Abatacept and Upadacitinib. Rheumatoid arthritis [FA20] [8]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Abatacept and Canakinumab. Rheumatoid arthritis [FA20] [9]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Abatacept and Rilonacept. Rheumatoid arthritis [FA20] [9]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Abatacept and Golimumab. Rheumatoid arthritis [FA20] [10]
Coadministration of a Drug Treating the Disease Different from Abatacept (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Abatacept and Roflumilast. Asthma [CA23] [8]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Abatacept and Denosumab. Low bone mass disorder [FB83] [11]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Abatacept and Tecfidera. Multiple sclerosis [8A40] [12]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Abatacept and Siponimod. Multiple sclerosis [8A40] [13]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Abatacept and Fingolimod. Multiple sclerosis [8A40] [14]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Abatacept and Ozanimod. Multiple sclerosis [8A40] [8]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Abatacept and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [15]
⏷ Show the Full List of 7 DDI Information of This Drug

References

1 Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. Clin Rev Allergy Immunol. 2018 Feb;54(1):68-87.
2 Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57.
3 Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice. Cell Commun Signal. 2023 Nov 9;21(1):321.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6891).
5 Systemic Lupus Erythematosus Management in Pregnancy. Int J Womens Health. 2022 Feb 15;14:199-211.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
10 Product Information. Orencia (abatacept). Bristol-Myers Squibb, Princeton, NJ.
11 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
12 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
15 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.